Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Dec;302(6):1353-1359.
doi: 10.1007/s00404-020-05728-7. Epub 2020 Aug 4.

Fetal and maternal outcome after hyperimmunoglobulin administration for prevention of maternal-fetal transmission of cytomegalovirus during pregnancy: retrospective cohort analysis

Vera Seidel  1 , Max Hackelöer  2 , Rebecca C Rancourt  3 , Wolfgang Henrich  2 , Jan-Peter Siedentopf  2
Affiliations
Observational Study

Fetal and maternal outcome after hyperimmunoglobulin administration for prevention of maternal-fetal transmission of cytomegalovirus during pregnancy: retrospective cohort analysis

Vera Seidel et al. Arch Gynecol Obstet. 2020 Dec.

Abstract

Purpose: To determine the frequency of fetal infection as well as adverse pregnancy outcomes following antenatal hyperimmunoglobulin (HIG) treatment for primary cytomegalovirus (CMV) infection in pregnancy.

Methods: In our observational cohort study, data from 46 women with a primary CMV infection during pregnancy were evaluated. Primary CMV infection was defined by seroconversion or the presence of CMV-IgM and low CMV-IgG avidity. All women received at least two or more infusions of HIG treatment (200 IU/kg). Congenital CMV infection (cCMV) was diagnosed by detection of CMV in amniotic fluid and/or neonatal urine. We compared the rate of maternal-fetal transmission from our cohort to data without treatment in the literature. The frequency of adverse pregnancy outcomes was compared to those of live-born infants delivered in our clinic.

Results: We detected 11 intrauterine infections in our cohort, which correlates to a transmission rate of 23.9%. Compared to the transmission rate found in cases without treatment (39.9%), this is a significant reduction (P = 0.026). There were no adverse pregnancy outcomes in our cohort. The mean gestational age at delivery was 39 weeks gestation in treatment and control group.

Conclusion: The administration of HIG for prevention of maternal-fetal CMV transmission during pregnancy seems safe and effective.

Keywords: Cytomegalovirus; Fetal transmission; Hyperimmunoglobulin; Pregnancy; Prevention of maternal.

PubMed Disclaimer

Conflict of interest statement

VS, MH, RCR, and WH declare that they have no conflict of interest. JPS has served as local PI in a prospective randomized trial on Cytotect® conducted by Biotest AG, Dreieich Germany. In this position, he has received travel grants to a study meeting and a conference on CMV in 2016.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ludwig A, Hengel H. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill. 2009;14(9):26–32. - PubMed
    1. Fowler KB, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326(10):663–667. doi: 10.1056/NEJM199203053261003. - DOI - PubMed
    1. Henrich W, et al. Recurrent cytomegalovirus infection during pregnancy: ultrasonographic diagnosis and fetal outcome. Ultrasound Obstet Gynecol. 2002;19(6):608–611. doi: 10.1046/j.1469-0705.2002.00705.x. - DOI - PubMed
    1. Kagan KO, Hamprecht K. Cytomegalovirus infection in pregnancy. Arch Gynecol Obstet. 2017;296(1):15–26. doi: 10.1007/s00404-017-4380-2. - DOI - PubMed
    1. Wang C, et al. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011;52(2):e11–e13. doi: 10.1093/cid/ciq085. - DOI - PubMed

Publication types

MeSH terms

Substances